Profile data is unavailable for this security.
About the company
Inno-Gene SA is a Poland-based holding company engaged in management of a portfolio of companies active in life-science sector through the technology, research and development. Inno-Gene SA’s portfolio comprises of Centrum Badan DNA Sp. z o.o., a company that provides services in the field of genetic medical diagnostics, including microbiological diagnosis of infection and the suitability of human congenital diseases using tests performed on DNA microarray technology. On March 22, 2013, the Company established a new subsidiary, Centrum Edukacji Bio-Medycznej Sp. z o.o. On April 11, 2013, the Company established two new indirect subsidiaries, Genomix Sp. z o.o. and Madgenetix Sp. z o.o. In addition, it operates through VitainSillica Sp z o o.
- Revenue in PLN (TTM)1.13m
- Net income in PLN-1.46m
- Incorporated2010
- Employees27.00
- LocationInno-Gene SAul. Sciegiennego 20POZNAN 60-128PolandPOL
- Phone+48 616468585
- Fax+48 616232526
- Websitehttp://www.inno-gene.pl/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Rented Sector SA | 200.00k | 27.20k | 8.59m | -- | 315.69 | -- | 91.60 | 42.95 | 0.0206 | 0.0206 | 0.1514 | -0.035 | 1.79 | -- | 2.20 | -- | 24.28 | 1,266.23 | -- | -- | 23.89 | -1,935.55 | 13.60 | 2,755.44 | -- | -- | -- | -- | -- | -- | -66.26 | -- | -- | -- |
| Inno-Gene SA | 1.13m | -1.46m | 10.26m | 27.00 | -- | 1.55 | -- | 9.10 | -0.2559 | -0.2559 | 0.1979 | 1.16 | 0.1086 | 4.67 | 0.673 | -- | -14.04 | 7.92 | -19.07 | 10.73 | 39.18 | 73.63 | -129.34 | 11.59 | 2.58 | -- | 0.0362 | -- | -93.08 | -16.73 | -542.12 | -- | -- | -- |
| Braster SA | 1.31m | -3.83m | 16.24m | 16.00 | -- | -- | -- | 12.42 | -0.2825 | -0.2825 | 0.0561 | -0.1734 | 0.0601 | 0.0769 | 163.38 | -- | -17.61 | -29.23 | -220.50 | -50.27 | 71.16 | 68.77 | -293.04 | -1,435.54 | 0.3061 | -2.59 | 1.62 | -- | 413.76 | 41.35 | 42.87 | -- | -- | -- |
| Sygnis SA | 15.75m | -8.22m | 17.17m | -- | -- | -- | -- | 1.09 | -0.3614 | -0.3614 | 0.6925 | -- | -- | -- | -- | -- | -- | -6.10 | -- | -9.57 | 50.82 | 56.46 | -53.74 | -22.44 | -- | -10.62 | -- | -- | -33.38 | 44.26 | -266.18 | -- | -- | -- |
| Nanogroup SA | 2.02k | -7.89m | 20.60m | -- | -- | 4.60 | -- | 10,197.97 | -0.3926 | -0.3926 | 0.0001 | 0.2228 | 0.0002 | 17.60 | 0.0349 | -- | -56.82 | -23.18 | -67.19 | -26.06 | -47,764.85 | -278.03 | -391,395.10 | -1,567.57 | 0.5186 | -2,409.12 | 0.00 | -- | -98.55 | -55.07 | -840.84 | -- | -8.99 | -- |
| Stem Cells Spin SA | -100.00bn | -100.00bn | 21.49m | -- | -- | 2.89 | -- | -- | -- | -- | -- | 0.1797 | -- | -- | -- | -- | -- | -1.14 | -- | -1.93 | -- | 94.37 | -- | -45.34 | 0.0363 | -- | 0.0153 | -- | 68.84 | -4.37 | -678.77 | -- | -52.67 | -- |
| Genxone SA | 2.39m | -3.72m | 23.41m | -- | -- | 1.56 | -- | 9.77 | -1.13 | -1.13 | 0.7265 | 4.54 | 0.1358 | 13.39 | 5.04 | -- | -21.09 | 14.58 | -22.04 | 16.46 | -23.18 | 48.42 | -155.31 | 20.41 | 16.91 | -- | 0.0039 | -- | -77.38 | 111.39 | -874.87 | -- | -28.78 | -- |
| Pure Biologics SA | 109.00k | -31.72m | 25.17m | 53.00 | -- | 1.93 | -- | 230.88 | -11.15 | -11.15 | 0.0377 | 4.05 | 0.0023 | -- | 0.1026 | 1,135.42 | -66.46 | -48.68 | -81.74 | -83.38 | -3,960.55 | 38.81 | -29,097.25 | -195.73 | -- | -11.41 | 0.7606 | -- | 160.63 | -7.58 | -117.62 | -- | -- | -- |
| Cannabis Poland SA | 199.93k | -675.76k | 28.24m | -- | -- | 51.85 | -- | 141.26 | -0.0255 | -0.0255 | 0.0076 | 0.0111 | 0.3018 | 0.8264 | 5.07 | -- | -102.76 | -116.92 | -175.94 | -136.30 | 26.16 | 12.29 | -340.53 | -959.39 | 1.35 | -45.88 | 0.2547 | -- | -47.55 | 50.23 | 14.30 | -- | -- | -- |
| GENOMED SA | 22.48m | 996.34k | 39.11m | -- | 39.25 | 3.86 | 24.22 | 1.74 | 0.7541 | 0.7541 | 17.01 | 7.66 | 2.00 | 6.29 | 13.81 | -- | 8.87 | 7.90 | 10.24 | 9.33 | 42.85 | 38.56 | 4.43 | 3.93 | 4.10 | 3,257.61 | -- | -- | 9.85 | 3.87 | 193.38 | -7.69 | -32.19 | -- |
| Inventionmed SA | 610.00 | -2.46m | 41.77m | 9.00 | -- | 7.79 | -- | 68,482.22 | -0.0121 | -0.0121 | 0.00 | 0.0264 | 0.00002 | -- | 0.0004 | 67.78 | -7.00 | -18.09 | -11.73 | -23.28 | -1,288.53 | -48.77 | -403,196.70 | -43,186.79 | -- | -2.11 | -- | -- | -85.01 | -- | 88.90 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Inno-Gene SA's reporting currency: Polish New Zloty PLN
0.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| TFI PZU SAas of 30 Jun 2020 | 0.00 | 0.00% |
Data from 30 Jun 2023 - 30 Jun 2023Source: FactSet Research Systems Inc.
